123 related articles for article (PubMed ID: 8684530)
41. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
Seifert A; von Herrath D; Schaefer K
Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
[TBL] [Abstract][Full Text] [Related]
42. Quantification of desferrioxamine, ferrioxamine and aluminoxamine by post-column derivatization high-performance liquid chromatography. Non-linear calibration resulting from second-order reaction kinetics.
Kraemer HJ; Breithaupt H
J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):191-204. PubMed ID: 9686887
[TBL] [Abstract][Full Text] [Related]
43. Aluminum removal in uremic patients after desferrioxamine infusion: is hemofiltration more effective than hemodialysis?
Winterberg B; Bertram HP
Nephron; 1990; 54(2):179. PubMed ID: 2314528
[No Abstract] [Full Text] [Related]
44. Effect of desferrioxamine infusion on red blood cell aluminum.
Umeda M; Umimoto K; Tsurusaki K; Izumi N; Kishimoto T; Maekawa M
ASAIO Trans; 1988; 34(3):297-9. PubMed ID: 3196524
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients.
Janssen MJ; van Boven WP
Pharm World Sci; 1996 Oct; 18(5):187-91. PubMed ID: 8933580
[TBL] [Abstract][Full Text] [Related]
46. Effect of body iron stores on serum aluminum level in hemodialysis patients.
Huang JY; Huang CC; Lim PS; Wu MS; Leu ML
Nephron; 1992; 61(2):158-62. PubMed ID: 1630539
[TBL] [Abstract][Full Text] [Related]
47. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.
Lee P; Mohammed N; Marshall L; Abeysinghe RD; Hider RC; Porter JB; Singh S
Drug Metab Dispos; 1993; 21(4):640-4. PubMed ID: 8104123
[TBL] [Abstract][Full Text] [Related]
48. Desferrioxamine infusion can modify EEG tracing in haemodialysed patients.
Brancaccio D; Avanzini G; Padovese P; Gallieni M; Franceschetti S; Panzica F; Anelli A; Colantonio G; Martinelli D; Bugiani O
Nephrol Dial Transplant; 1991; 6(4):264-8. PubMed ID: 1881580
[TBL] [Abstract][Full Text] [Related]
49. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
Navarro JA; Granadillo VA; Rodríguez-Iturbe B; García R; Salgado O; Romero RA
Clin Nephrol; 1991 May; 35(5):213-7. PubMed ID: 1855329
[TBL] [Abstract][Full Text] [Related]
50. Management of iron overload in dialysis patients.
Winchester JF
Semin Nephrol; 1986 Dec; 6(4 Suppl 1):22-6. PubMed ID: 3299589
[TBL] [Abstract][Full Text] [Related]
51. Concomitant removal of aluminium and iron by haemodialysis and haemofiltration after desferrioxamine intravenous infusion.
Ciancioni C; Poignet JL; Naret C; Delons S; Mauras Y; Allain P; Man NK
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():469-73. PubMed ID: 3991542
[TBL] [Abstract][Full Text] [Related]
52. Absorption and biodistribution of 111indium-labelled desferrioxamine (111In-DFO) after subcutaneous injection of 111In-DFO liposomes.
Postma NS; Boerman OC; Oyen WJ; Zuidema J; Storm G
J Control Release; 1999 Mar; 58(1):51-60. PubMed ID: 10021489
[TBL] [Abstract][Full Text] [Related]
53. Quantifying Intranasally Administered Deferoxamine in Rat Brain Tissue with Mass Spectrometry.
Kosyakovsky J; Witthuhn BA; Svitak AL; Frey WH; Hanson LR; Fine JM
ACS Chem Neurosci; 2019 Nov; 10(11):4571-4578. PubMed ID: 31573798
[TBL] [Abstract][Full Text] [Related]
54. Thrombocytopenia associated with intravenous desferrioxamine.
Walker JA; Sherman RA; Eisinger RP
Am J Kidney Dis; 1985 Oct; 6(4):254-6. PubMed ID: 4050784
[TBL] [Abstract][Full Text] [Related]
55. Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis.
Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T
ASAIO Trans; 1986; 32(1):52-7. PubMed ID: 3778761
[TBL] [Abstract][Full Text] [Related]
56. Desferrioxamine treatment for aluminium and iron overload in uraemic patients by haemodialysis or haemofiltration.
Baldamus CA; Schmidt H; Scheuermann EH; Werner E; Kaltwasser JP; Schoeppe W
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():382-6. PubMed ID: 3991527
[TBL] [Abstract][Full Text] [Related]
57. Deferoxamine pharmacokinetics.
Porter JB
Semin Hematol; 2001 Jan; 38(1 Suppl 1):63-8. PubMed ID: 11206963
[TBL] [Abstract][Full Text] [Related]
58. Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa.
Obolensky A; Berenshtein E; Lederman M; Bulvik B; Alper-Pinus R; Yaul R; Deleon E; Chowers I; Chevion M; Banin E
Free Radic Biol Med; 2011 Oct; 51(8):1482-91. PubMed ID: 21824515
[TBL] [Abstract][Full Text] [Related]
59. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
von Bonsdorff M; Sipilä R; Pitkänen E
Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
[TBL] [Abstract][Full Text] [Related]
60. Recent developments in iron chelation therapy.
Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
